Literature DB >> 9700508

Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes.

E J Collins1, J A Frelinger.   

Abstract

Class I proteins are responsible for binding proteins from endogenously synthesized proteins and displaying them on the cell surface. Our understanding of this process has reached the point where we can manipulate the biochemical properties of peptide/class I binding and determine the effects of this alteration on subsequent immune responses. In this article, we will review the biochemistry of peptide/class I binding, and the effects of structure on this interaction between class I proteins and their peptide ligands. We will review the data which suggest that the major relevant biochemical parameter of class I peptide binding is the off-rate. We will show that the design of altered ligands with improved binding, thermostability and immunogenicity is possible.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700508     DOI: 10.1111/j.1600-065x.1998.tb01194.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  5 in total

Review 1.  Rational design of peptide-based tumor vaccines.

Authors:  Wilson S Meng; Lisa H Butterfield
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

2.  Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism.

Authors:  Crystal Morales Del Valle; Joseph R Maxwell; Maria M Xu; Antoine Menoret; Payal Mittal; Naomi Tsurutani; Adam J Adler; Anthony T Vella
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

3.  Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4.

Authors:  M Peakman; E J Stevens; T Lohmann; P Narendran; J Dromey; A Alexander; A J Tomlinson; M Trucco; J C Gorga; R M Chicz
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

4.  Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu.

Authors:  Matthew A Joseph; Megan L Mitchell; Jeffrey D Evanseck; Jeffrey R Kovacs; Liang Jia; Hongmei Shen; Wilson S Meng
Journal:  Mol Immunol       Date:  2006-04-04       Impact factor: 4.407

Review 5.  Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Authors:  Ravi A Madan; Philip M Arlen; Mahsa Mohebtash; James W Hodge; James L Gulley
Journal:  Expert Opin Investig Drugs       Date:  2009-07       Impact factor: 6.206

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.